Astrazeneca PLC (NYSE:AZN) – Equities researchers at Jefferies Group increased their FY2017 earnings per share estimates for shares of Astrazeneca PLC in a research note issued to investors on Tuesday. Jefferies Group analyst J. Holford now forecasts that the company will post earnings per share of $1.89 for the year, up from their prior estimate of $1.85. Jefferies Group currently has a “Hold” rating on the stock. Jefferies Group also issued estimates for Astrazeneca PLC’s FY2021 earnings at $2.72 EPS.

Several other research analysts have also weighed in on AZN. BidaskClub lowered Astrazeneca PLC from a “sell” rating to a “strong sell” rating in a research report on Friday. Cowen and Company reissued a “hold” rating and issued a $34.00 price objective on shares of Astrazeneca PLC in a research report on Friday, July 28th. Morgan Stanley lowered Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a research report on Friday, July 28th. Pareto Securities raised Astrazeneca PLC from a “sell” rating to a “hold” rating in a research report on Tuesday. Finally, Leerink Swann lowered Astrazeneca PLC from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $36.00 to $31.00 in a research report on Thursday, July 27th. Four research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the company. Astrazeneca PLC currently has a consensus rating of “Hold” and an average target price of $33.39.

ILLEGAL ACTIVITY WARNING: “Astrazeneca PLC (AZN) to Post FY2017 Earnings of $1.89 Per Share, Jefferies Group Forecasts” was published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/08/05/astrazeneca-plc-azn-to-post-fy2017-earnings-of-1-89-per-share-jefferies-group-forecasts.html.

Astrazeneca PLC (AZN) opened at 30.17 on Thursday. The firm has a market capitalization of $76.39 billion, a PE ratio of 19.79 and a beta of 0.74. The firm has a 50-day moving average price of $33.57 and a 200-day moving average price of $31.37. Astrazeneca PLC has a 1-year low of $25.55 and a 1-year high of $35.60.

Astrazeneca PLC (NYSE:AZN) last posted its earnings results on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.46. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The firm had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. During the same period in the previous year, the firm earned $0.83 earnings per share. The company’s revenue was down 9.9% on a year-over-year basis.

The business also recently declared a None dividend, which will be paid on Monday, September 11th. Shareholders of record on Friday, August 11th will be paid a dividend of $0.44 per share. The ex-dividend date of this dividend is Wednesday, August 9th. This represents a yield of 2.98%. Astrazeneca PLC’s dividend payout ratio (DPR) is currently 44.92%.

A number of institutional investors have recently added to or reduced their stakes in the stock. Hudock Capital Group LLC increased its position in Astrazeneca PLC by 0.4% in the first quarter. Hudock Capital Group LLC now owns 6,773 shares of the company’s stock worth $210,000 after buying an additional 27 shares during the period. First Financial Bank N.A. Trust Division increased its position in Astrazeneca PLC by 0.7% in the first quarter. First Financial Bank N.A. Trust Division now owns 7,517 shares of the company’s stock worth $234,000 after buying an additional 50 shares during the period. Beacon Investment Advisory Services Inc. increased its position in Astrazeneca PLC by 0.7% in the first quarter. Beacon Investment Advisory Services Inc. now owns 7,571 shares of the company’s stock worth $236,000 after buying an additional 54 shares during the period. Garrison Financial Corp increased its position in Astrazeneca PLC by 0.5% in the second quarter. Garrison Financial Corp now owns 18,058 shares of the company’s stock worth $616,000 after buying an additional 86 shares during the period. Finally, Parkside Financial Bank & Trust increased its position in Astrazeneca PLC by 1.3% in the first quarter. Parkside Financial Bank & Trust now owns 7,040 shares of the company’s stock worth $219,000 after buying an additional 90 shares during the period. Institutional investors and hedge funds own 14.39% of the company’s stock.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Earnings History and Estimates for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.